Elanco backs FY25 adjusted EPS view 80c-86c, consensus 83c

Raises FY25 revenue view to $4.51B-$4.58B from $4.45B-$4.51B, consensus $4.5B. Backs FY25 adjusted EBITDA view $830M-$870M. “We are raising our 2025 full-year revenue guidance and maintaining our adjusted EBITDA and adjusted EPS ranges, reflecting our strong first quarter execution, recent momentum and more favorable foreign exchange rates, balanced by expected tariff impact and a cautious approach in an uncertain macroeconomic environment,” said Todd Young, Executive Vice President and CFO of Elanco (ELAN) Animal Health. “On tariffs, we have taken several intervention actions, positioning us well to cover potential impacts with or without the pharmaceutical exemption. We are also accelerating our debt paydown to approximately half a billion dollars this year, now expecting to end 2025 with a net leverage ratio of 3.9x to 4.3x.”